Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective

Carrasco, L R and Lee, V J and Chen, M I and Matchar, D B and Thompson, J P and Cook, A R (2011): Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. Published in: Journal of the Royal Society Interface , Vol. 8, No. 62 (7 September 2011): pp. 1301-1313.

Abstract

Influenza pandemics present a global threat owing to their potential mortality and substantial economic impacts. Stockpiling antiviral drugs to manage a pandemic is an effective strategy to offset their negative impacts; however, little is known about the long-term optimal size of the stockpile under uncertainty and the characteristics of different countries. Using an epidemic–economic model we studied the effect on total mortality and costs of antiviral stockpile sizes for Brazil, China, Guatemala, India, Indonesia, New Zealand, Singapore, the UK, the USA and Zimbabwe. In the model, antivirals stockpiling considerably reduced mortality. There was greater potential avoidance of expected costs in the higher resourced countries (e.g. from $55 billion to $27 billion over a 30 year time horizon for the USA) and large avoidance of fatalities in those less resourced (e.g. from 11.4 to 2.3 million in Indonesia). Under perfect allocation, higher resourced countries should aim to store antiviral stockpiles able to cover at least 15 per cent of their population, rising to 25 per cent with 30 per cent misallocation, to minimize fatalities and economic costs. Stockpiling is estimated not to be cost-effective for two-thirds of the world's population under current antivirals pricing. Lower prices and international cooperation are necessary to make the life-saving potential of antivirals cost-effective in resource-limited countries.

• Item Type: MPRA Paper
• Language: English
• Keywords: Antiviral Drugs, Health Economics, Influenza, Uncertainty
• Subjects: I - Health, Education, and Welfare > I1 - Health; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

Anderson, R. M. & May, R. M. 1992. Infectious diseases of humans: dynamics & control., Oxford University Press.

Balicer, R. D., Huerta, M., Davidovitch, N. & Grotto, I. 2005. Cost-benefit of stockpiling drugs for influenza pandemic. Emerging Infectious Diseases, 11, 1280-1282.

Chow, A., Ma, S., Ling, A. E. & Chew, S. K. 2006. Influenza-associated deaths in the tropical Singapore. Emerging Infectious Diseases, 12.

Cooper, B., Pitman, R., Edmunds, W. & Gay, N. 2006. Delaying the international spread of a pandemic influenza. PLoS Med, 3, e212. doi:10.1371/journal.pmed.0030212.

Dhankhar, P., Dasbach, E. J. & Elbasha, E. H. 2009. Economics of stockpiling for an influenza pandemic. Lancet Infectious Diseases, 9, 459-460.

Diekmann, O. & Heesterbeek, J. A. P. 2000 Mathematical epidemiology of infectious diseases, Chichester: Wiley.

Ferguson, N., Mallet, S., Jackson, H., Roberts, N. & Ward, P. 2003. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother, 51, 977 - 990.doi: 10.1093/jac/dkg136

Ferguson, N. M., Cummings, D. A. T., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S. & Burke, D. S. 2005. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature, 437, 209-214. doi:10.1038/nature04017

Ferguson, N. M., Cummings, D. A. T., Fraser, C., Cajka, J. C., Cooley, P. C. & Burke, D. S. 2006. Strategies for mitigating an influenza pandemic. Nature, 442, 448-452. doi:10.1038/nature04795

Fraser, C., Donnelly, C. A., Cauchemez, S., Hanage, W. P., Van Kerkhove, M. D., Hollingsworth, T. D., Griffin, J., Baggaley, R. F., Jenkins, H. E., Lyons, E. J., Jombart, T., Hinsley, W. R., Grassly, N. C., Balloux, F., Ghani, A. C., Ferguson, N. M., Rambaut, A., Pybus, O. G., Lopez-Gatell, H., Alpuche-Aranda, C. M., Chapela, I. B., Zavala, E. P., Guevara, D. M. E., Checchi, F., Garcia, E., Hugonnet, S., Roth, C. & W. H. O. Rapid Pandemic Assessment Coll. 2009. Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings. Science, 324, 1557-1561.doi: 10.1126/science.1176062

Germann, T. C., Kadau, K., Longini, I. M. & Macken, C. A. 2006. Mitigation strategies for pandemic influenza in the United States. Proceedings of the National Academy of Sciences of the United States of America, 103, 5935-5940.doi: 10.1073/pnas.0601266103

Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D. & Basser, R. L. 2009. Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine -- Preliminary Report. N Engl J Med, NEJMoa0907413.

Hayden, F. G. 2001. Perspectives on antiviral use during pandemic influenza. Philosophical Transactions of the Royal Society of London Series B-Biological Sciences, 356, 1877-1884.doi: 10.1098/rstb.2001.1007

Jackson, H. C., Roberts, N., Wang, Z. M. & Belshe, R. 2000. Management of influenza - Use of new antivirals and resistance in perspective. Clinical Drug Investigation, 20, 447-454.

Koopmanschap, M. A., Rutten, F. F. H., Vanineveld, B. M. & Vanroijen, L. 1995. The friction cost method for measuring indirect costs of disease. Journal of Health Economics, 14, 171-189. doi:10.1016/0167-6296(94)00044-5

Lee, V. J., Phua, K. H., Chen, M. I., Chow, A., Ma, S., Goh, K. T. & Leo, Y. S. 2006. Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerging Infectious Diseases, 12, 95-102.

Lee, V. J., Yap, J., Cook, A. R., Chen, M. I., Tay, J. K., Tan, B. H., Loh, J. P., Chew, S. W., Koh, W. H., Lin, R., Cui, L., Lee, C. W. H., Sung, W.-K., Wong, C. W., Hibberd, M. L., Kang, W. L., Seet, B. & Tambyah, P. A. 2010. Oseltamivir Ring Prophylaxis for Containment of 2009 H1N1 Influenza Outbreaks. N Engl J Med, 362, 2166-2174.

Longini, I. M., Jr., Halloran, M. E., Nizam, A. & Yang, Y. 2004. Containing Pandemic Influenza with Antiviral Agents. Am. J. Epidemiol., 159, 623-633.doi: 10.1093/aje/kwh092

Lugnér, A. K., Mylius, S. D. & Wallinga, J. 2009. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Economics, 19, 518-531.

Lugnér, A. K. & Postma, M. J. 2009. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur J Public Health, ckp119. doi: 10.1093/eurpub/ckp119

Lund, R. 2007. Revenge of the White Swan. The American Statistician, 61, 189-192.

Mengewein. 2009. Roche Cuts Tamiflu Price for Developing Countries. Wall Street Journal.

Mills, C. E., Robins, J. M. & Lipsitch, M. 2004. Transmissibility of 1918 pandemic influenza. Nature, 432, 904-906.doi:10.1038/nature03063

Murray, C. J. L., Lopez, A. D., Chin, B., Feehan, D. & Hill, K. H. 2006. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet, 368, 2211-2218.doi:10.1016/S0140-6736(06)69895-4

Nordhaus, W. 2007. Critical Assumptions in the Stern Review on Climate Change. Science, 317, 201-202. doi: 10.1126/science.1137316

Potter, C. W. 2001. A history of influenza. Journal of Applied Microbiology, 91, 572-579.doi: 10.1046/j.1365-2672.2001.01492.x

Roberts, M. G. 2007. The pluses and minuses of R0. Journal of the Royal Society Interface, 4, 949-961. doi: 10.1098/rsif.2007.1031

Sachs, J. D. 2001. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, Switzerland, 2001. Available at: http://whqlibdoc.who.int/publications/2001/924154550X.pdf.

Sander, B., Nizam, A., Garrison, L. P., Postma, M. J., Halloran, M. E. & Longini, I. M. 2009. Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model. Value in Health, 12, 226-233.

Siddiqui, M. R. & Edmunds, W. J. 2008. Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic. Emerging Infectious Diseases, 2, 267-274.

Taleb, N. N. 2007. The Black Swan: The Impact of the Highly Improbable, Random House.

Towers, S. & Feng, Z. 2009. Pandemic H1N1 influenza: predicting the course of a pandemic and assessing the efficacy of the planned vaccination programme in the United States. Eurosurveillance, 14, 6-8.